Ge Long Hui·2026-03-22 23:11Group 1 - The core viewpoint of the article highlights that China National Pharmaceutical Group (国药控股) is expected to achieve revenue growth that outpaces the overall industry by the end of 2025, with a focus on enhancing market share and operational efficiency [1][2] - For the fiscal year ending December 31, 2025, the company reported total revenue of RMB 575.168 billion, a year-on-year decrease of 1.6%, while net profit reached RMB 10.834 billion, reflecting a year-on-year increase of 3.94% [1] - The company proposed a final dividend of RMB 0.69 per share, totaling approximately RMB 2.153 billion, indicating a commitment to returning value to shareholders [1] Group 2 - The company has implemented a cost-leading strategy and lean management practices, resulting in a 0.25 percentage point decrease in overall expense ratio by the end of 2025, effectively offsetting the decline in gross profit [1] - Operating cash flow showed a net inflow of RMB 14.138 billion, an increase of RMB 2.592 billion compared to the previous year, demonstrating effective cash flow management [1] - The company’s accounts receivable growth has significantly narrowed, and the asset-liability ratio decreased by 2.12 percentage points year-on-year, showcasing improved internal governance and resilience against market fluctuations [1] Group 3 - In 2025, the company aims to focus on high-quality development, assessing regional market conditions and competitive landscapes to actively expand market share through reform and innovation [2] - The three main business segments exhibited differentiated development, with the pharmaceutical distribution segment accounting for 72.79% of revenue, a slight decrease of 0.37 percentage points; the medical device distribution segment at 19.32%, down 0.09 percentage points; and the pharmaceutical retail segment at 6.42%, up 0.50 percentage points [2]